- Home
- ADGM vs PRTG Comparison
ADGM vs PRTG Comparison
Compare ADGM & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- PRTG
- Stock Information
- Founded
- ADGM 2011
- PRTG 1973
- Country
- ADGM United States
- PRTG British Virgin Islands
- Employees
- ADGM N/A
- PRTG N/A
- Industry
- ADGM
- PRTG Oil & Gas Production
- Sector
- ADGM
- PRTG Energy
- Exchange
- ADGM NYSE
- PRTG Nasdaq
- Market Cap
- ADGM 19.7M
- PRTG 17.7M
- IPO Year
- ADGM N/A
- PRTG N/A
- Fundamental
- Price
- ADGM $1.38
- PRTG $5.91
- Analyst Decision
- ADGM
- PRTG
- Analyst Count
- ADGM 0
- PRTG 0
- Target Price
- ADGM N/A
- PRTG N/A
- AVG Volume (30 Days)
- ADGM 44.3K
- PRTG 231.7K
- Earning Date
- ADGM 08-25-2025
- PRTG 08-26-2025
- Dividend Yield
- ADGM N/A
- PRTG N/A
- EPS Growth
- ADGM N/A
- PRTG N/A
- EPS
- ADGM N/A
- PRTG N/A
- Revenue
- ADGM $576,000.00
- PRTG N/A
- Revenue This Year
- ADGM N/A
- PRTG N/A
- Revenue Next Year
- ADGM N/A
- PRTG N/A
- P/E Ratio
- ADGM N/A
- PRTG N/A
- Revenue Growth
- ADGM 116.54
- PRTG N/A
- 52 Week Low
- ADGM $0.63
- PRTG $2.10
- 52 Week High
- ADGM $9.34
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- PRTG 45.85
- Support Level
- ADGM N/A
- PRTG $5.60
- Resistance Level
- ADGM N/A
- PRTG $6.20
- Average True Range (ATR)
- ADGM 0.00
- PRTG 0.42
- MACD
- ADGM 0.00
- PRTG 0.10
- Stochastic Oscillator
- ADGM 0.00
- PRTG 65.45
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.